News Releases
by Year
2019
Dec. 28, 2019 (PDF/115KB) Corporate
Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
Dec. 23, 2019 (PDF/488KB) R&D
Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
Dec. 20, 2019 (PDF/244KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
Dec. 13, 2019 (PDF/217KB) Licensing
SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
Dec. 04, 2019 (PDF/126KB) R&D
Boston Biomedical, Inc. Enters into an Alliance in Oncology Research with Columbia University, Harvard University and The Wistar Institute
Dec. 02, 2019 Sustainability
Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
Nov. 27, 2019 (PDF/114KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officer and Other Key Positions
Nov. 27, 2019 (PDF/2,758KB) Sustainability
ESG Meeting (Discussion with Investors)
Nov. 25, 2019 (PDF/641KB) R&D
Sunovion Resubmits New Drug Application for Apomorphine Sublingual Film
Nov. 14, 2019 (PDF/425KB) R&D
iPS Cell Research Discovers Common Pathologies in Psychiatric Disorders Elucidation of the Pathogenesis of Bipolar Disorder and Schizophrenia May Find Application in Therapeutic Drug Development
Nov. 08, 2019 Corporate
Posted Video of Investors Meeting Presentation for Q2 FY2019 (April 1 to September 30, 2019) ／Definitive Agreement for Strategic Alliance with Roivant Sciences [Webcast]
Oct. 31, 2019 (PDF/1,705KB) Corporate
Investors Meeting Presentation for Q2 FY2019 (April 1 to September 30, 2019) ／Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 31, 2019 (PDF/1,557KB) Corporate
Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 31, 2019 (PDF/186KB) Corporate
Sumitomo Dainippon Pharma and Roivant Sciences Sign a Definitive Agreement for a Strategic Alliance
Oct. 31, 2019 (PDF/103KB) Corporate
【Joint press release】Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Oct. 28, 2019 (PDF/926KB) Finances
Press Conference Presentation for Q2 FY2019 (April 1 to September 30, 2019)
Oct. 28, 2019 (PDF/537KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2020
Oct. 28, 2019 (PDF/318KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2020
Oct. 21, 2019 (PDF/177KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the half-year period ending September 30, 2019
Oct. 21, 2019 (PDF/141KB) Sustainability
Sumitomo Dainippon Pharma Contributes to the Typhoon Hagibis in October 2019 in Japan
Oct. 18, 2019 (PDF/237KB) Corporate
Sumitomo Dainippon Pharma announces Change in Executive Officer
Oct. 17, 2019 (PDF/94KB) Corporate
Comments on Acquisition Proposal to Australian Stem Cell and Regenerative Medicine Company
Sep. 12, 2019 Corporate
Posted Conference Call for Memorandum of Understanding for Strategic Alliance with Roivant Sciences [Webcast]
Sep. 06, 2019 (PDF/477KB) Corporate
Presentation Material（Memorandum of Understanding for Strategic Alliance with Roivant Sciences）
Sep. 06, 2019 (PDF/269KB) Corporate
Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding for a Strategic Alliance
Sep. 06, 2019 (PDF/224KB) Corporate
【Joint press release】Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
Sep. 03, 2019 (PDF/82KB) Products
Sumitomo Dainippon Pharma to Launch Atypical Antipsychotic LONASEN Tape in Japan
Sep. 03, 2019 (PDF/106KB) Products
Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China
Aug. 29, 2019 (PDF/244KB) Corporate
Sumitomo Dainippon Pharma announces Investment in a Venture Capital Fund
Aug. 01, 2019 Finances
Posted Conference Call for Q1 FY2019 [Webcast]
Jul. 31, 2019 (PDF/123KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Lurasidone in Japan for the Treatment of Schizophrenia and Bipolar Depression
Jul. 31, 2019 (PDF/173KB) R&D
Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
Jul. 29, 2019 (PDF/582KB) Finances
Presentation Material (First Quarter Financial Results for FY2019)
Jul. 29, 2019 (PDF/457KB) Finances
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2020
Jul. 29, 2019 (PDF/301KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2020 [IFRS]
Jul. 29, 2019 (PDF/139KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Jul. 25, 2019 (PDF/151KB) Sustainability
Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index
Jul. 25, 2019 (PDF/109KB) Corporate
Sumitomo Dainippon Pharma to Enter Into an Investment Agreement with Drawbridge Health
Jul. 22, 2019 (PDF/240KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Clinical Study of LONASEN, an Atypical Antipsychotic Agent, in the Treatment of Adolescent Patients with Schizophrenia in Japan
Jul. 19, 2019 (PDF/80KB) Corporate
Comments on Announcement by Australian Stem Cell and Regenerative Medicine Company
Jul. 09, 2019 (PDF/340KB) Sustainability
Sumitomo Dainippon Pharma and National Center for Global Health and Medicine Initiate International Project on Measures against Antimicrobial Resistance (AMR) and Promote the Proper Use of Antibiotics in Vietnam
Jul. 02, 2019 (PDF/125KB) R&D
Sumitomo Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Pancreatic Cancer Following Interim Analysis
Jun. 25, 2019 (PDF/169KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes
Jun. 18, 2019 (PDF/87KB) Products
Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical Antipsychotic LONASEN Tape in Japan
Jun. 17, 2019 (PDF/241KB) Corporate
Sumitomo Dainippon Pharma announces Personnel Changes
Jun. 13, 2019 (PDF/82KB) R&D
Sumitomo Dainippon Pharma announces Changes to Agreement on Joint Development of Treatments for Eye Diseases Using iPS Cell-derived Retinal Pigment Epithelial Cells in Japan
Jun. 07, 2019 (PDF/127KB) R&D
Sumitomo Dainippon Pharma Announces Recommendation to Continue Phase 3 CanStem303C Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Colorectal Cancer Following Interim Analysis
May 30, 2019 (PDF/110KB) Licensing
Sumitomo Dainippon Pharma Signs a Co-Promotion and Sales Collaboration Agreement for Diabetes Treatments Equa and EquMet in Japan
May 22, 2019 (PDF/86KB) Products
Sumitomo Dainippon Pharma to Launch RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
May 16, 2019 Finances
Posted Video of Investors Meeting Presentation for FY2018 [Webcast]
May 10, 2019 (PDF/608KB) Finances
Presentation Material (Financial Results for FY2018)
May 10, 2019 (PDF/461KB) Finances
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2019
May 10, 2019 (PDF/267KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2019 [IFRS]
May 10, 2019 (PDF/217KB) Corporate
Sumitomo Dainippon Pharma announces Changes in Board of Directors
May 10, 2019 (PDF/574KB) R&D
Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
May 08, 2019 (PDF/128KB) Corporate
Sumitomo Dainippon Pharma to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S.
Apr. 26, 2019 (PDF/56KB) Corporate
Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2019
Apr. 19, 2019 (PDF/113KB) Finances
Sumitomo Dainippon Pharma Revises Financial Forecasts
Apr. 19, 2019 Finances
Posted Video of Mid-term Business Plan 2022 [Webcast]
Apr. 11, 2019 (PDF/4,486KB) Finances
Presentation Material (Mid-term Business Plan 2022)
Apr. 11, 2019 (PDF/83KB) Finances
Sumitomo Dainippon Pharma Announces Mid-term Business Plan 2022(FY2018 - FY2022)
Apr. 09, 2019 (PDF/167KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
Apr. 09, 2019 (PDF/101KB) R&D
GHIT Fund Awards Grant for Continuing Development of Malaria Vaccine Discovered by Ehime University and Sumitomo Dainippon Pharma
Apr. 05, 2019 (PDF/143KB) R&D
Five Partners Commence Joint R&D on Renal Regenerative Medicine
Apr. 02, 2019 (PDF/81KB) R&D
Sumitomo Dainippon Pharma Submits an Application of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Mar. 28, 2019 (PDF/118KB) Corporate
AlphaNavi Pharma Established as a Carve-Out Business Venture from Sumitomo Dainippon Pharma with Investment
Mar. 26, 2019 (PDF/49KB) Products
Sumitomo Dainippon Pharma Receives Approval in Japan for RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
Mar. 12, 2019 (PDF/5,765KB) Finances
Sumitomo Chemical Announces the New Corporate Business Plan FY2019 - FY2021
Mar. 04, 2019 (PDF/172KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Mar. 04, 2019 (PDF/94KB) Corporate
Sumitomo Dainippon Pharma Expands Roles and Responsibilities of Subsidiary in Singapore and Establishes Subsidiary in Thailand
Feb. 08, 2019 (PDF/140KB) R&D
Sumitomo Dainippon Pharma and Aikomi Conclude Joint Research Agreement on Medical Devices to Relieve Behavioral and Psychological Symptoms of Dementia
Feb. 05, 2019 Finances
Posted Conference Call for Q3 FY2018 [Webcast]
Jan. 31, 2019 (PDF/591KB) Finances
Presentation Material (Third Quarter Financial Results for FY2018)
Jan. 31, 2019 (PDF/451KB) Finances
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2019
Jan. 31, 2019 (PDF/548KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2019 [IFRS]
Jan. 31, 2019 (PDF/161KB) R&D
Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
Jan. 29, 2019 (PDF/39KB) Products
Sumitomo Dainippon Pharma Announces the Approval of Atypical Antipsychotic Latuda (lurasidone HCl) for the Treatment of Patients with Schizophrenia in China
Jan. 29, 2019 (PDF/302KB) R&D
SanBio and Sumitomo Dainippon Pharma Announce Topline Results from a Phase 2b Study in the U.S. Evaluating SB623, a Regenerative Cell Medicine for the Treatment of Patients with Chronic Stroke
Jan. 10, 2019 (PDF/86KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase III Clinical Study (JEWEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia